Biosimilars Rise Is Cold Comfort For Biogen As Tecfidera Competition Bites
Signals ‘Financial Reset’ In 2021 Due To Dimethyl Fumarate Generics
Biosimilars sales rising by 8% to almost $800m in 2020 failed to offset the impact on Biogen of generic competition to its Tecfidera brand in the US.
You may also be interested in...
Sandoz has announced its launch of a generic rival to Tecfidera in Canada, with the firm among the first generics to be issued a notice of compliance by Health Canada.
In an exclusive interview, Samsung Bioepis’ head of clinical research, Il Sun Hong, tells Generics Bulletin how the company managed to put itself at the head of the pack in the chase for biosimilar Eylea (aflibercept); and how the biosimilar can coexist with biosimilars to Lucentis (ranibizumab), which may debut later this year.
The company sees aducanumab adding a modest boost to sales if approved, but there are another four Phase III programs with some major read-outs coming.